Analysts Set Sage Therapeutics, Inc. (NASDAQ:SAGE) PT at $16.06

Sage Therapeutics, Inc. (NASDAQ:SAGE) has been assigned a consensus recommendation of “Reduce” from the nineteen analysts that are covering the firm, Marketbeat.com reports. Two analysts have rated the stock with a sell rating, sixteen have given a hold rating and one has assigned a buy rating to the company. The average 12-month price objective among brokerages that have updated their coverage on the stock in the last year is $16.06.

SAGE has been the topic of several analyst reports. Truist Financial decreased their target price on shares of Sage Therapeutics from $18.00 to $13.00 and set a “hold” rating on the stock in a research note on Wednesday, August 14th. Robert W. Baird decreased their price objective on shares of Sage Therapeutics from $15.00 to $13.00 and set a “neutral” rating on the stock in a research report on Thursday, July 25th. Scotiabank dropped their target price on shares of Sage Therapeutics from $19.00 to $17.00 and set a “sector outperform” rating for the company in a report on Thursday, July 25th. Mizuho lowered their price target on Sage Therapeutics from $18.00 to $16.00 and set a “neutral” rating for the company in a research report on Friday, July 19th. Finally, JPMorgan Chase & Co. cut their price objective on Sage Therapeutics from $12.00 to $10.00 and set a “neutral” rating on the stock in a research report on Tuesday, August 6th.

Hedge Funds Weigh In On Sage Therapeutics

Large investors have recently modified their holdings of the stock. Vanguard Group Inc. raised its holdings in Sage Therapeutics by 8.1% in the first quarter. Vanguard Group Inc. now owns 5,751,373 shares of the biopharmaceutical company’s stock worth $107,781,000 after buying an additional 432,013 shares during the last quarter. RTW Investments LP raised its stake in shares of Sage Therapeutics by 0.9% in the fourth quarter. RTW Investments LP now owns 5,197,019 shares of the biopharmaceutical company’s stock worth $112,619,000 after purchasing an additional 47,537 shares during the last quarter. Bellevue Group AG raised its position in Sage Therapeutics by 27.1% in the 1st quarter. Bellevue Group AG now owns 4,465,544 shares of the biopharmaceutical company’s stock worth $83,684,000 after buying an additional 952,193 shares during the last quarter. Price T Rowe Associates Inc. MD grew its stake in shares of Sage Therapeutics by 69.8% in the first quarter. Price T Rowe Associates Inc. MD now owns 811,934 shares of the biopharmaceutical company’s stock worth $15,217,000 after acquiring an additional 333,805 shares during the period. Finally, Federated Hermes Inc. purchased a new stake in Sage Therapeutics during the 2nd quarter valued at $7,281,000. Hedge funds and other institutional investors own 99.22% of the company’s stock.

Sage Therapeutics Trading Up 6.4 %

Shares of NASDAQ:SAGE opened at $7.83 on Monday. The stock has a market capitalization of $478.02 million, a P/E ratio of -0.93 and a beta of 0.91. The stock’s 50-day moving average price is $9.40 and its 200-day moving average price is $12.66. Sage Therapeutics has a 12-month low of $7.19 and a 12-month high of $28.26.

Sage Therapeutics (NASDAQ:SAGE) last posted its quarterly earnings results on Wednesday, July 31st. The biopharmaceutical company reported ($1.70) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.68) by ($0.02). Sage Therapeutics had a negative return on equity of 55.87% and a negative net margin of 458.30%. The company had revenue of $8.65 million for the quarter, compared to the consensus estimate of $8.85 million. During the same quarter in the previous year, the business earned ($2.68) earnings per share. Sage Therapeutics’s revenue was up 249.8% compared to the same quarter last year. As a group, research analysts predict that Sage Therapeutics will post -6.47 EPS for the current year.

Sage Therapeutics Company Profile

Sage Therapeutics, Inc, a biopharmaceutical company, develops and commercializes brain health medicines. Its product candidates include ZULRESSO, a CIV injection for the treatment of postpartum depression (PPD) in adults; and ZURZUVAE, a neuroactive steroid, a positive allosteric modulator of GABAA receptors, targeting both synaptic and extrasynaptic GABAA receptors, for the treatment of postpartum depression.